NYSE:PKI - PerkinElmer Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $93.07 -0.44 (-0.47 %) (As of 02/21/2019 12:56 PM ET)Previous Close$93.51Today's Range$92.71 - $93.3252-Week Range$70.83 - $98.33Volume3,606 shsAverage Volume591,895 shsMarket Capitalization$10.35 billionP/E Ratio25.76Dividend Yield0.30%Beta1.24 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and Precipio, Inc. The company was founded in 1931 and is headquartered in Waltham, Massachusetts. Receive PKI News and Ratings via Email Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorComputer and Technology Current SymbolNYSE:PKI Previous Symbol CUSIP71404610 Webwww.perkinelmer.com Phone781-663-6900Debt Debt-to-Equity Ratio0.73 Current Ratio1.60 Quick Ratio1.16Price-To-Earnings Trailing P/E Ratio25.76 Forward P/E Ratio23.09 P/E Growth1.89 Sales & Book Value Annual Sales$2.78 billion Price / Sales3.73 Cash Flow$5.3985 per share Price / Cash Flow17.24 Book Value$23.24 per share Price / Book4.00Profitability EPS (Most Recent Fiscal Year)$3.61 Net Income$237.92 million Net Margins8.56% Return on Equity15.89% Return on Assets6.79%Miscellaneous Employees11,000 Outstanding Shares111,240,000Market Cap$10.35 billion OptionableOptionable PerkinElmer (NYSE:PKI) Frequently Asked Questions What is PerkinElmer's stock symbol? PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI." How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer? PerkinElmer declared a quarterly dividend on Thursday, January 24th. Shareholders of record on Friday, April 19th will be given a dividend of $0.07 per share on Friday, May 10th. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Wednesday, April 17th. View PerkinElmer's Dividend History. How were PerkinElmer's earnings last quarter? PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings results on Thursday, January, 31st. The medical research company reported $1.18 EPS for the quarter, topping the consensus estimate of $1.16 by $0.02. The medical research company had revenue of $756.35 million for the quarter, compared to analyst estimates of $746.15 million. PerkinElmer had a net margin of 8.56% and a return on equity of 15.89%. During the same period in the previous year, the company posted $0.97 EPS. View PerkinElmer's Earnings History. When is PerkinElmer's next earnings date? PerkinElmer is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for PerkinElmer. What guidance has PerkinElmer issued on next quarter's earnings? PerkinElmer issued an update on its FY19 earnings guidance on Thursday, January, 31st. The company provided earnings per share guidance of $4.00-4.05 for the period, compared to the Thomson Reuters consensus estimate of $4.03. What price target have analysts set for PKI? 13 analysts have issued 12 month price targets for PerkinElmer's shares. Their predictions range from $44.50 to $104.00. On average, they anticipate PerkinElmer's stock price to reach $80.5717 in the next year. This suggests that the stock has a possible downside of 13.4%. View Analyst Price Targets for PerkinElmer. What is the consensus analysts' recommendation for PerkinElmer? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer. Has PerkinElmer been receiving favorable news coverage? Press coverage about PKI stock has trended somewhat negative on Thursday, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PerkinElmer earned a coverage optimism score of -1.7 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of PerkinElmer's key competitors? Some companies that are related to PerkinElmer include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO) and HTG Molecular Diagnostics (HTGM). Who are PerkinElmer's key executives? PerkinElmer's management team includes the folowing people: Mr. Robert F. Friel, Chairman, CEO & Pres (Age 62)Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 49)Mr. James Corbett, Exec. VP & Pres of Discovery and Analytical Solutions (Age 55)Mr. Prahlad R. Singh, Exec. VP & Pres of Diagnostics (Age 53)Mr. James M. Mock, Sr. VP & CFO Who are PerkinElmer's major shareholders? PerkinElmer's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.29%), Massachusetts Financial Services Co. MA (3.39%), King Luther Capital Management Corp (2.26%), Geode Capital Management LLC (1.37%), Northern Trust Corp (0.96%) and Lord Abbett & CO. LLC (0.92%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Institutional Ownership Trends for PerkinElmer. Which institutional investors are selling PerkinElmer stock? PKI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Treasurer State of Michigan, Impax Asset Management Group plc, First National Bank of Omaha, Lord Abbett & CO. LLC, Robecosam AG, Barclays PLC and Rothschild & Co. Asset Management US Inc.. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Insider Buying and Selling for PerkinElmer. Which institutional investors are buying PerkinElmer stock? PKI stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Massachusetts Financial Services Co. MA, Geode Capital Management LLC, Public Employees Retirement System of Ohio, Thrivent Financial for Lutherans, First Citizens Bank & Trust Co., Bank of America Corp DE and SG Americas Securities LLC. View Insider Buying and Selling for PerkinElmer. How do I buy shares of PerkinElmer? Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is PerkinElmer's stock price today? One share of PKI stock can currently be purchased for approximately $93.00. How big of a company is PerkinElmer? PerkinElmer has a market capitalization of $10.35 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.92 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 11,000 workers across the globe. What is PerkinElmer's official website? The official website for PerkinElmer is http://www.perkinelmer.com. How can I contact PerkinElmer? PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected] MarketBeat Community Rating for PerkinElmer (NYSE PKI)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 400 (Vote Outperform)Underperform Votes: 416 (Vote Underperform)Total Votes: 816MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is net income?